Aandelen in “Fabricage van farmaceutische preparaten”

Aandeel Datum Koers Evolutie
Even geduld...

Nieuws over “Fabricage van farmaceutische preparaten”

12/08 · Acquisition of Own Shares · Persbericht

12/08 · Acquisition of Own Shares · Persbericht

12/08 · Inkoop van eigen aandelen · Persbericht

12/08 · PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program · Persbericht

12/08 · Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP · Persbericht

12/08 · CAPR UPCOMING DEADLINE: Levi & Korsinsky Alerts Capricor Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm · Persbericht

12/08 · Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis · Persbericht

12/08 · Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market · Persbericht

12/08 · Are SUNS, VREX, CHMI, FBRX Obtaining Fair Deals for their Shareholders? · Persbericht

11/08 · EBS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Emergent BioSolutions · Persbericht

11/08 · Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI · Persbericht

11/08 · Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy · Persbericht

11/08 · Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices · Persbericht

11/08 · CAPR Investor Announcement: Capricor Therapeutics Sued on behalf of Investors to Recover Losses after Clinical Data Leads to 64% Stock Drop · Persbericht

11/08 · AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD) · Persbericht

11/08 · CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit · Persbericht

11/08 · Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update · Persbericht

11/08 · Zymeworks Announces Participation in Upcoming Investor Conferences · Persbericht

11/08 · Lakefront Biotherapeutics dringt operationeel verlies terug · Tijd.be (€)

ont Biotherapeutics, voorheen Galapagos, noteerde over de eerste jaarhelft een operationeel verlies van 107 miljoen euro. Dat is grosso modo een halvering ten opzichte van de eerste helft van 2025.

11/08 · Emergent BioSolutions Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Emergent BioSolutions (EBS) · Persbericht

10/08 · Immunic Appoints Elena Ridloff to Board of Directors · Persbericht

Mijn selecties